These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28242812)

  • 1. CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.
    Lal S; Cheung EC; Zarei M; Preet R; Chand SN; Mambelli-Lisboa NC; Romeo C; Stout MC; Londin E; Goetz A; Lowder CY; Nevler A; Yeo CJ; Campbell PM; Winter JM; Dixon DA; Brody JR
    Mol Cancer Res; 2017 Jun; 15(6):696-707. PubMed ID: 28242812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttranscriptional Regulation of
    Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
    Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
    Jimbo M; Blanco FF; Huang YH; Telonis AG; Screnci BA; Cosma GL; Alexeev V; Gonye GE; Yeo CJ; Sawicki JA; Winter JM; Brody JR
    Oncotarget; 2015 Sep; 6(29):27312-31. PubMed ID: 26314962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
    Zhou H; Telonis AG; Jing Y; Xia NL; Biederman L; Jimbo M; Blanco F; Londin E; Brody JR; Rigoutsos I
    Cell Death Dis; 2016 Jul; 7(7):e2294. PubMed ID: 27415424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
    Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.
    Romeo C; Weber MC; Zarei M; DeCicco D; Chand SN; Lobo AD; Winter JM; Sawicki JA; Sachs JN; Meisner-Kober N; Yeo CJ; Vadigepalli R; Tykocinski ML; Brody JR
    Mol Cancer Res; 2016 Jul; 14(7):599-611. PubMed ID: 27053682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells.
    Dong R; Chen P; Polireddy K; Wu X; Wang T; Ramesh R; Dixon DA; Xu L; Aubé J; Chen Q
    Mol Cancer Ther; 2020 Nov; 19(11):2267-2277. PubMed ID: 32879054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.
    Peng W; Furuuchi N; Aslanukova L; Huang YH; Brown SZ; Jiang W; Addya S; Vishwakarma V; Peters E; Brody JR; Dixon DA; Sawicki JA
    Mol Cell Biol; 2018 Feb; 38(3):. PubMed ID: 29133460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.
    Zarei M; Lal S; Parker SJ; Nevler A; Vaziri-Gohar A; Dukleska K; Mambelli-Lisboa NC; Moffat C; Blanco FF; Chand SN; Jimbo M; Cozzitorto JA; Jiang W; Yeo CJ; Londin ER; Seifert EL; Metallo CM; Brody JR; Winter JM
    Cancer Res; 2017 Aug; 77(16):4460-4471. PubMed ID: 28652247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.
    Brown SZ; McCarthy GA; Carroll JR; Di Niro R; Pelz C; Jain A; Sutton TL; Holly HD; Nevler A; Schultz CW; McCoy MD; Cozzitorto JA; Jiang W; Yeo CJ; Dixon DA; Sears RC; Brody JR
    Mol Cell Biol; 2022 Jul; 42(7):e0001822. PubMed ID: 35703534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.
    Blanco FF; Preet R; Aguado A; Vishwakarma V; Stevens LE; Vyas A; Padhye S; Xu L; Weir SJ; Anant S; Meisner-Kober N; Brody JR; Dixon DA
    Oncotarget; 2016 Nov; 7(45):74043-74058. PubMed ID: 27677075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α1,6-Fucosyltransferase contributes to cell migration and proliferation as well as to cancer stemness features in pancreatic carcinoma.
    Liang C; Fukuda T; Isaji T; Duan C; Song W; Wang Y; Gu J
    Biochim Biophys Acta Gen Subj; 2021 Jun; 1865(6):129870. PubMed ID: 33571582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
    Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA.
    Xiao H; Ye X; Vishwakarma V; Preet R; Dixon DA
    Cancer Biol Ther; 2022 Dec; 23(1):139-149. PubMed ID: 35130122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
    Zarei M; Lal S; Vaziri-Gohar A; O'Hayer K; Gunda V; Singh PK; Brody JR; Winter JM
    Mol Cancer Res; 2019 Feb; 17(2):508-520. PubMed ID: 30266754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.
    Dhir T; Schultz CW; Jain A; Brown SZ; Haber A; Goetz A; Xi C; Su GH; Xu L; Posey J; Jiang W; Yeo CJ; Golan T; Pishvaian MJ; Brody JR
    Mol Cancer Res; 2019 Oct; 17(10):2029-2041. PubMed ID: 31383722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of GPRC5a on the Proliferation, Migration Ability, Chemotherapy Resistance, and Phosphorylation of GSK-3β in Pancreatic Cancer.
    Liu B; Yang H; Pilarsky C; Weber GF
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29949874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.
    Blanco FF; Jimbo M; Wulfkuhle J; Gallagher I; Deng J; Enyenihi L; Meisner-Kober N; Londin E; Rigoutsos I; Sawicki JA; Risbud MV; Witkiewicz AK; McCue PA; Jiang W; Rui H; Yeo CJ; Petricoin E; Winter JM; Brody JR
    Oncogene; 2016 May; 35(19):2529-41. PubMed ID: 26387536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.